home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550866.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
31 lines
Document 0866
DOCN M9550866
TI Modulation of interferon-mediated inhibition of human immunodeficiency
virus type 1 by Tat.
DT 9505
AU Shirazi Y; Popik W; Pitha PM; Oncology Center, Johns Hopkins University
School of Medicine,; Baltimore, MD 21231.
SO J Interferon Res. 1994 Oct;14(5):259-63. Unique Identifier : AIDSLINE
MED/95165002
AB Recently, we have shown that in acutely infected T cells interferons
(IFNs) effectively inhibit the human immunodeficiency type 1 (HIV-1)
proviral DNA synthesis during a single replication cycle. In the present
study, we have evaluated the relative effectiveness of IFNs in
restricting HIV-1 expression at post-transcriptional level. Treatment of
HeLa cells with IFNs A* and B (up to 1,000 U/ml) did not result in a
reduction in HIV-1 RNA and protein synthesis encoded by the transfected
HIV-1 proviral clone. Interestingly, IFN treatment reduced significantly
the HIV-1 mRNA levels encoded by the transfected tat-defective HIV-1
provirus, and this inhibition could be overcome by transfection with
Tat- and Rev-expressing plasmids. These results suggest that
HIV-1-encoded Tat and Rev can overcome the inhibitory effects of IFNs on
HIV-1 replication.
DE Gene Products, tat/*BIOSYNTHESIS Hela Cells Human HIV-1/*DRUG
EFFECTS/GENETICS Interferons/*PHARMACOLOGY RNA Processing,
Post-Transcriptional Support, Non-U.S. Gov't Support, U.S. Gov't,
P.H.S. Virus Replication/*DRUG EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).